Conditions: HCMV Reactivation or HCMV End-Organ Disease
Keywords: HCMV
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 133
Healthy volunteers: no

Brief summary:
The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).

Detailed description:

Arms:
arm 1: 60 mg AIC246, one tablet per day arm 2: 120 mg AIC246, one tablet per day arm 3: 240 mg AIC246, one tablet per day arm 4: Placebo arm

Interventions: intervention 1: 60 mg AIC246 intervention 2: 120 mg AIC246 intervention 3: 240 mg AIC246 intervention 4: Placebo
Intervention descriptions: intervention 1: Oral administration intervention 2: Oral administration intervention 3: Oral administration intervention 4: Oral administration

Protocol document: